The role of benzodiazepines in treating social anxiety disorder

American Journal of Psychiatry

Volumn 171, Issue 7, 2014, Pages 795-

  Silberman, Edward K ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE; CLONAZEPAM;

CLINICAL EFFECTIVENESS; DRUG ABUSE; DRUG DEPENDENCE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HUMAN; LETTER; PRIORITY JOURNAL; RISK ASSESSMENT; SOCIAL PHOBIA; SUBSTANCE ABUSE; TREATMENT INDICATION; TREATMENT RESPONSE;

ANTI-ANXIETY AGENTS; CLONAZEPAM; CYCLOHEXANOLS; FEMALE; HUMANS; MALE; PHOBIC DISORDERS; SERTRALINE;

EID: 84903583074     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2014.14010048     Document Type: Letter

References (5)

1. Pollack MH, Van Ameringen M, Simon NM, Worthington JW, Hoge EA, Keshaviah A, Stein MB: A double-blind randomized controlled trial of augmentation and switch strategies for refractory social anxiety disorder. Am J Psychiatry 2014; 171:44-53
2. Berney P, Halperin D, Tango R, Daeniker-Dayer I, Schulz P: A major change of prescribing pattern in absence of adequate evidence: benzodiazepines versus newer antidepressants in anxiety disorders. Psychopharmacol Bull 2008; 41:39-47
3. Davidson JR, Potts N, Richichi E, Krishnan R, Ford SM, Smith R, Wilson WH: Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacol 1993; 13:423-428 (Pubitemid 24026104)
4. Woods JH, Winger G: Current benzodiazepine issues. Psychopharmacology (Berl) 1995; 118:107-115, discussion 118, 120-121
5. Posternak MA, Mueller TI: Assessing the risks and bene fits of benzodiazepines for anxiety disorders in patients with a history of substance abuse or dependence. Am J Addict 2001; 10:48-68 (Pubitemid 32201733)